Radiopharm Theranostics Limited (RADX)

Market Cap	44.88M
Revenue (ttm)	8.20M
Net Income (ttm)	-25.14M
Shares Out	2.36B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,568
Open	5.70
Previous Close	5.75
Day's Range	4.97 - 5.75
52-Week Range	3.50 - 50.82
Beta	0.80
Analysts	Strong Buy
Price Target	15.00 (+160.87%)
Earnings Date	n/a

About RADX

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: RADX

Financial Performance

In 2025, Radiopharm Theranostics's revenue was 12.51 million, an increase of 538.86% compared to the previous year's 1.96 million. Losses were -38.34 million, -20.04% less than in 2024.

Financial numbers in AUD

Analyst Forecast

According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 160.87% from the latest price.

Price Target

$15.0

(160.87% upside)

Analyst Consensus: Strong Buy